Physician profile
Alejandro Dominguez
NPI 1619532942
$4,707.81
in general payments reported to CMS, 2019-2025
17 companies · $2,135 in 2025
The $2,135 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $13.86 · 2021: $23.39 · 2022: $303 · 2023: $661 · 2024: $1,572 · 2025: $2,135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,367.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,296.34 | 2021-2025 | Cobalt Dr Mri Surescan, Onyx Frontier, Aurora Ev-Icd Mri Surescan |
| Boston Scientific Corporation | $646.19 | 2022-2025 | Watchman Flx, Stingray, Avvigo Guidance System |
| Abbott Laboratories | $532.61 | 2024-2025 | Navitor, Diamondback Coronary, Ultreon |
| Amgen INC. | $352.36 | 2022-2024 | Repatha |
| Edwards Lifesciences Corporation | $281.00 | 2025 | Sapien 3 Ultra Resilia, Evoque, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Stryker Corporation | $265.83 | 2025 | Flowtriever |
| Atricure, INC. | $227.84 | 2022-2023 | |
| Philips North America LLC | $218.98 | 2024 | (Bh4) Igt Devices Undivided |
| Astrazeneca Pharmaceuticals Lp | $188.15 | 2020-2023 | Farxiga |
| Chiesi USA, INC. | $172.53 | 2024 | Kengreal |
| Abiomed | $147.97 | 2025 | |
| Penumbra, INC. | $143.00 | 2025 | Indigo System |
| Terumo Medical Corporation | $72.53 | 2024-2025 | Angio-Seal, Heartrail, Glidewire |
| Actelion Pharmaceuticals US, INC. | $68.01 | 2024-2025 | Uptravi, Opsumit, Opsynvi |
| United Therapeutics Corporation | $32.10 | 2025 | Tyvaso |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $31.25 | 2025 | |
| Merck Sharp & Dohme LLC | $31.12 | 2024 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Dominguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.